Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis (OCS) published notifications dated Dec 9, 2025 reporting the vesting and settlement of restricted stock units (RSUs) previously granted to company directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oculis (OCS) published notifications dated Dec 9, 2025 reporting the vesting and settlement of restricted stock units (RSUs) previously granted to company directors. The notifications name four directors: Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, and indicate these RSUs vested/settled in December 2025.
These are routine managers' transaction disclosures concerning executive/director compensation events; no financial amounts or additional terms were included in the text provided.
Details
News Market Reaction – OCS
On Dec 10, the first trading day after this news, OCS closed 0.54% above the previous close.
Data tracked by StockTitan Argus for the Dec 10 session.
Key Figures
- Share price
- $20.59
- Prior to RSU vesting news; 24h change -5.03%
- 52-week range
- $14.00 – $23.08
- Price is 10.79% below 52-week high
- Cash & ST investments
- $182 million
- As of Sept 30, 2025; runway into 2H 2027
- Shares in F-3 resale
- 494,259 shares
- Ordinary shares registered for resale via warrant-linked F-3
- Potential warrant proceeds
- $6,877,246.59
- If all registered warrants are fully exercised in cash
- Equity financing gross
- $110.0 million
- Underwritten and direct offerings announced Oct 31, 2025
- Estimated net proceeds
- $102.5 million
- Combined net from underwritten and direct offerings
- ACUITY vision gain
- 18 letters at 3 months
- Phase 2 ACUITY trial topline result for Privosegtor
Historical Context
-
Disclosure of RSU vesting and settlement for director Arshad Khanani.
-
Manager’s transaction notice for RSU vesting by director Arshad Khanani.
-
Positive FDA meeting enabling registrational PIONEER program for Privosegtor.
-
Notification of ordinary share purchase by director Lionel Carnot.
-
Positive Phase 2 ACUITY data for Privosegtor in acute optic neuritis.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
persons discharging managerial responsibilities regulatory
RSUs financial
vesting financial
settlement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Attachments
- Notification of managers' transaction - Anthony Rosenberg - December 2025 RSU vest
- Notification of managers' transaction - Christina Ackermann - December 2025 RSU vest
- Notification of managers' transaction - Arshad Khanani - December 2025 RSU vest
- Notification of managers' transaction - Robert Warner - December 2025 RSU vest
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.